

# 49311

# **MARK3 Antibody**



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

#### For Research Use Only. Not for Use in Diagnostic Procedures.

<b>Applications:</b> W, IP	<b>Reactivity:</b> H M R	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 83	<b>Source/Isotype:</b> Rabbit	<b>UniProt ID:</b> #P27448	Entrez-Gene Id: 4140	
Product Usage Information		<b>Application</b> Western Blotting Immunoprecipitation	<b>Dilution</b> 1:1000 ion 1:50				
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 $\mu$ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.					
Specificity/Sensitivity		MARK3 Antibody detects endogenous levels of total MARK3 protein. No cross-reactivity is observed with other family members.					
Species predicted to react based on 100% sequence homology		Monkey, Bovine, Dog					
Source / Purification		Polyclonal antibodies are produced by immunizing animals with a synthetic peptide surrounding Asn500 of human MARK3. Antibodies were purified by protein A and peptide affinity chromatography.					
Background		Microtubule associated proteins regulate the stability of microtubules and control processes such as cell polarity/differentiation, neurite outgrowth, cell division and organelle trafficking (1). The MARK (MAP/microtubule affinity-regulating kinases) family (MARK1-4) of serine/threonine kinases was identified based on their ability to phosphorylate microtubule-associated proteins (MAPs) including tau, MAP2 and MAP4 (2-6). MARK proteins phosphorylate MAPs within their microtubule binding domains, causing dissociation of MAPs from microtubules and increased microtubule dynamics (2-4). In the case of tau, phosphorylation has been hypothesized to contribute to the formation of neurofibrillary tangles observed in Alzheimer's disease. Overexpression of MARK leads to hyperphosphorylation of MAPs, morphological changes and cell death (4). The tumor suppressor kinase LKB1 phosphorylates MARK and the closely related AMP-kinases within their T-loops, leading to increased activity (7). MARK3 is an ubiquitously expressed member of the MARK/EMK/Par-1 family that was identified as Cdc25C-associated protein kinase (C-TAK1) based on its association and ability to phosphorylate Cdc25C (8). MARK3 substrates include Cdc25C phosphatase, MAPK scaffold kinase suppressor of Ras1 (KSR1) (9), protein-tyrosine phosphatase H1 (PTPH1) (10), plakophilin 2 (PKP2) (11), and histone deacetylases (HDACs) (12). MARK3 phosphorylates Cdc25C on serine 216 in response to DNA damage which allows for the preferential binding of 14-3-3 proteins that control entry into mitosis (8). MARK3 has also been shown to phosphorylate HDAC7 on one of its 14-3-3 binding sites that effects both the subcellular localization and repressive function of the HDAC (12).					
Background References		2. Illenberger, S. et al. (19 3. Drewes, G. et al. (19 4. Drewes, G. et al. (19 5. Kato, T. et al. (2001) 6. Trinczek, B. et al. (20 7. Lizcano, J.M. et al. (2 8. Peng, C.Y. et al. (199 9. Müller, J. et al. (2001 10. Zhang, S.H. et al. (1	Drubin, D.G. and Nelson, W.J. (1996) <i>Cell</i> 84, 335-44.  Illenberger, S. et al. (1996) <i>J Biol Chem</i> 271, 10834-43.  Drewes, G. et al. (1995) <i>J Biol Chem</i> 270, 7679-88.  Drewes, G. et al. (1997) <i>Cell</i> 89, 297-308.  Kato, T. et al. (2001) <i>Neoplasia</i> 3, 4-9.  Trinczek, B. et al. (2004) <i>J Biol Chem</i> 279, 5915-23.  Lizcano, J.M. et al. (2004) <i>EMBO J</i> 23, 833-43.  Peng, C.Y. et al. (1998) <i>Cell Growth Differ</i> . 9, 197-208.  Müller, J. et al. (2001) <i>Mol. Cell</i> 8, 983-993.  D. Zhang, S.H. et al. (1997) <i>J. Biol. Chem</i> . 272, 27281-27287.  I. Müller, J. et al. (2003) <i>EMBO J</i> . 22, 4431-4442.  D. Dequiedt, F. et al. (2006) <i>Mol. Cell Biol</i> . 26, 7086-7102.				

## **Species Reactivity**

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

### **Western Blot Buffer**

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

**Applications Key** W: Western Blotting **IP**: Immunoprecipitation

Cross-Reactivity Key H: Human M: Mouse R: Rat

**Trademarks and Patents** Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for

more information.

**Limited Uses** 

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.